Wall Street Analysts Think Regenxbio Could Surge 234.37%: Read This Before Placing a Bet earnings, Regenxbio, Zacks Rank, price targets, EPS estimates, Wall Street analysts, short-term price targets by https://www.benzinga.com/
AI Insights:
Simple Explanation:
Some people who study stocks think that a company called Regenxbio will do better in the future and its stock price will go up a lot. They have different opinions on how much the stock price will go up, but they mostly agree that it will go up. This article tells us that it might be a good idea to invest in this company's stock because it has a chance to do well. Read from source...
Critical Perspective:
- The stock has gained 17.7% in the past four weeks
- The mean price target of $41.83 indicates a potential upside of 234.4%
- The standard deviation is $9.47, indicating a high degree of agreement among analysts
- Strong agreement in earnings estimate revisions also points to an upside
- The article acknowledges the limitations of analyst price targets and the need for further research
- The article provides a chart and links to more earnings updates
- The article ends with a promotional section for Benzinga
Investment Analysis:
We are not financial advisors. It's always essential for you to consult with a financial advisor and do your research before making any decisions about investments.
- Long RGNX at $12.51 with a 20% stop-loss and a 250% profit target.
- Short DIA at $337.54 with a 10% stop-loss and a 10% profit target.